Related references
Note: Only part of the references are listed.Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis
Yimeng Gao et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review
Qiang Zhang et al.
VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE (2020)
siRNA-mediated silencing of PAI-1 gene acts as a promoter over the recanalization of endothelial progenitor cells in rats with venous thrombosis
Hang Li et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Circulating miR-30c as a predictive biomarker of type 2 diabetes mellitus with coronary heart disease by regulating PAI-1/VN interactions
Mao Luo et al.
LIFE SCIENCES (2019)
Role of plasminogen activator inhibitor-1 in coronary pathophysiology
Richard G. Jung et al.
THROMBOSIS RESEARCH (2018)
Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin
M. Luo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Mechanisms of plasminogen activator inhibitor 1 action in stromal remodeling and related diseases
Jelena Milenkovic et al.
BIOMEDICAL PAPERS-OLOMOUC (2017)
Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions
Mehmet Agirbasli et al.
CARDIOVASCULAR THERAPEUTICS (2017)
Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up
Aslak Rautio et al.
DIABETES & VASCULAR DISEASE RESEARCH (2016)
Livedoid vasculopathy: A review of pathogenesis and principles of management
Biju Vasudevan et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2016)
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies
James Yarmolinsky et al.
SCIENTIFIC REPORTS (2016)
Noncoding RNAs, cytokines, and inflammation-related diseases
Jose Luiz Marques-Rocha et al.
FASEB JOURNAL (2015)
Associations Between Inflammatory Markers, Hemostatic Markers, and Microvascular Complications in 182 Chinese Patients With Type 2 Diabetes Mellitus
Nengneng Zheng et al.
LABMEDICINE (2015)
Compression-induced HIF-1 enhances thrombosis and PAI-1 expression in mouse skin
Maki Kaneko et al.
WOUND REPAIR AND REGENERATION (2015)
Associations Between Inflammatory Markers, Hemostatic Markers, and Microvascular Complications in 182 Chinese Patients With Type 2 Diabetes Mellitus
Nengneng Zheng et al.
LABMEDICINE (2015)
Plasminogen Activator Inhibitor-1 Regulates LPS-Induced TLR4/MD-2 Pathway Activation and Inflammation in Alveolar Macrophages
Weiying Ren et al.
INFLAMMATION (2015)
Livedoid Vasculopathy: Clinical Features and Treatment in 24 Chinese Patients
Suying Feng et al.
ACTA DERMATO-VENEREOLOGICA (2014)
Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis
Young Ho Lee et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2014)
Promoter variants of VTN are associated with vascular disease
Yibo Wang et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin
Paul J. Declerck et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2013)
Glycosylation influences the stability of human plasminogen activator inhibitor-1
Britt Van de Craen et al.
BLOOD COAGULATION & FIBRINOLYSIS (2012)
PAI-1 in tissue fibrosis
Asish K. Ghosh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
miR-421 and miR-30c Inhibit SERPINE 1 Gene Expression in Human Endothelial Cells
Alexandre Marchand et al.
PLOS ONE (2012)
Crystal Structure of Plasminogen Activator Inhibitor-1 in an Active Conformation with Normal Thermodynamic Stability
Jan K. Jensen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy
Mehmet Agirbasli et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Livedoid Vasculopathy Associated with Plasminogen Activator Inhibitor-1 Promoter Homozygosity (4G/4G) and Prothrombin G20210A Heterozygosity: Response to t-PA Therapy
Joana Antunes et al.
ACTA DERMATO-VENEREOLOGICA (2010)
Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats
R. Serrano et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2009)
Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation
Z. Ma et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2009)
Polymorphisms of MTHFR gene associated with livedoid vasculopathy in Taiwanese population
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2009)
Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin
Helen Brogren et al.
THROMBOSIS RESEARCH (2008)
Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia
Rosemarijn Renckens et al.
BLOOD (2007)
Livedoid vasculopathy - further evidence for procoagulant pathogenesis
Bethany R. Hairston et al.
ARCHIVES OF DERMATOLOGY (2006)
Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator
April Deng et al.
ARCHIVES OF DERMATOLOGY (2006)
Pericytes influence endothelial cell growth characteristics: Role of plasminogen activator inhibitor type 1 (PAI-1)
M McIlroy et al.
CARDIOVASCULAR RESEARCH (2006)
Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta 1
JS Vande Berg et al.
WOUND REPAIR AND REGENERATION (2005)
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
GO Hjortland et al.
EXPERIMENTAL CELL RESEARCH (2004)
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers
M Weckroth et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Biochemical importance of glycosylation of plasminogen activator inhibitor-I
A Gils et al.
THROMBOSIS AND HAEMOSTASIS (2003)
Prediction of the risk of myocardial infarction from polymorphisms in candidate genes
Y Yamada et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): Mapping the binding sites on PAI-1 and Vn
F Schroeck et al.
BIOLOGICAL CHEMISTRY (2002)
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent
L Devy et al.
FASEB JOURNAL (2002)
Plasminogen activator inhibitor type-1 (part one): Basic mechanisms, regulation, and role for thromboembolic disease
K Huber
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2001)
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice
DT Eitzman et al.
BLOOD (2000)
Share Paper
